TAMARA PARRISH: Open Payments
NPI 1316111727 · GALLATIN, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$733 in 47 payments from 13 companies in 2025. Trend: 2023 $37 · 2024 $610 · 2025 $733
Food & beverage: $733
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $267 |
| Sumitomo Pharma America, Inc. | 3 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $76 |
| Novo Nordisk Inc | 3 | $66 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
Products named: UBRELVY, VRAYLAR, GEMTESA, CAPLYTA, REXULTI, Ozempic, BREZTRI, INGREZZA.
Industry payments across TN — which companies pay providers there.
